GU Cancers 2022

ASCO Genitourinary Cancers Symposium

17–19 February 2022 | San Francisco, CA

From world-class science to patient-centered care, the 2022 ASCO Genitourinary (GU) Cancers Symposium offered new, innovative findings in the study, diagnosis, and treatment of GU malignancies. Catch up on key trials in prostate, bladder and kidney cancer, including findings from the PROpel, ARASENS, and BAYOU studies and more.

View all videos

; VJ Oncology @VJOncology ·

July 25, 2024 1816520901640232974

🎥@ldawsonmd of @UofT discusses SBRT for localized colorectal cancers, emphasizing its potential to improve survival. SBRT should complement, not replace, surgery and systemic therapies:

➡️⬅️

@myESMO #ESMOGI24 #RadOnc #CRCsm #ColorectalCancer

Stereotactic body radiation therapy for treating colon cancer

Laura Dawson, MD, University of Toronto, Toronto, Canada, discusses stereotactic body radiation therapy (SBRT) for treat...

ow.ly

Reply on Twitter 1816520901640232974 Retweet on Twitter 1816520901640232974 0 Like on Twitter 1816520901640232974 0 Twitter 1816520901640232974

; VJ Oncology @VJOncology ·

July 24, 2024 1816217008591020204

🎥@AlexisLevee of @CityofHope discusses a study on gut microbiome's link to response in metastatic #breastcancer treated with ICIs. Future studies aim to personalize treatments and develop probiotics:

➡️⬅️

@ASCO @OncoAlert #ASCO24 #ImmunoOnc #BCsm

Using gut microbiota to enhance immunotherapy for breast cancer

Alexis Ann LeVee, MD, City of Hope, Duarte, CA, comments on a Phase I/II study (NCT02778685) that revealed the g...

ow.ly

Reply on Twitter 1816217008591020204 Retweet on Twitter 1816217008591020204 0 Like on Twitter 1816217008591020204 2 Twitter 1816217008591020204

; VJ Oncology @VJOncology ·

July 24, 2024 1816154875320791124

🎥@drlauragoff of @VUMC_Cancer discusses the CheckMate 9DW trial, showing nivolumab + ipilimumab improved OS in advanced HCC vs. sorafenib or lenvatinib, outperforming IMbrave150 and HIMALAYA trials:

➡️⬅️

@ASCO @OncoAlert #ASCO24 #CTSM #ImmunoOnc #HPBCsm

CheckMate 9DW: the future of checkpoint inhibitors in advanced HCC

Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, provides insight on the CheckMate ...

ow.ly

Reply on Twitter 1816154875320791124 Retweet on Twitter 1816154875320791124 4 Like on Twitter 1816154875320791124 10 Twitter 1816154875320791124

; VJ Oncology @VJOncology ·

July 23, 2024 1815683327220687321

JULY is #Sarcoma Awareness Month 📣 💡

Check out this interview with Vaishali Kumar, MBBS from #AACR2024 | CCNG1 as a #biomarker for DRG-101 gene therapy in #cancer 🎥 🔦

👉

#VJOncology #Oncologynews #SarcomaAwarenessMonth

CCNG1 as a biomarker for DRG-101 gene therapy in cancer

Vaishali Kumar, MBBS, Sarcoma Oncology Research Center, Santa Monica, CA, discusses findings from an analysis of CCNG1...

www.vjoncology.com

Reply on Twitter 1815683327220687321 Retweet on Twitter 1815683327220687321 0 Like on Twitter 1815683327220687321 0 Twitter 1815683327220687321

; VJ Oncology @VJOncology ·

July 23, 2024 1815658499692515392

🎥@ChiaraCrem1 of @Unipisa discusses HRQoL from the CheckMate 8HW study on first-line nivolumab + ipilimumab vs. chemo in MSI-H/dMMR mCRC. Checkpoint inhibitors improved HRQoL significantly:

➡️⬅️

#ESMOGI24 @myESMO #CTSM #ImmunoOnc #CRCsm

CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRC

Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, discusses the health-related quality of life (HRQoL) outco...

ow.ly